We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers... read more Featured Products: More products

Download Mobile App





Nova Biomedical Demonstrates Whole Blood Critical and POC Testing Solutions at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021

Nova Biomedical (Waltham, MA, USA) demonstrated its whole blood critical and POC testing solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30. More...

The event provided an unparalleled opportunity to connect with global leaders in laboratory medicine, and to discover cutting edge technology & vital research in the field.

Nova is a world leader in whole blood critical and POC testing, offering hospital meters (including StatStrip Glucose, the only FDA-cleared meter for critically ill testing) and Stat Profile Prime critical care blood gas analyzers. At AACC 2021, Nova demonstrated its Stat Profile Prime Plus - a comprehensive, whole blood critical care analyzer that offers blood gases, electrolytes, metabolites, hematology, and co-oximetry, in a simple, compact device. Prime Plus combines maintenance-free, replaceable cartridge technology for sensors and reagents with patented, maintenance-free, and non-lysing whole blood co-oximetry technology. The analyzer uses a small 135µL sample, produces a complete 22-test panel in about one minute, and offers automated quality control with real-time, supplement quality monitoring of each sample analysis, calibration, and QC analysis. Prime Plus is the only critical care analyzer that includes BUN, creatinine, ionized magnesium, estimated plasma volume, and MCHC in its test menu. The complete test menu includes pH, PCO2, PO2, Na, K, Cl, iCa, iMg, Glucose, Lactate, BUN/Urea, Creatinine, Hct, Hb, estimated Plasma Volume, MCHC, SO2%, and CO-Oximetry.

At AACC 2021, Nova also displayed the StatStrip Glucose Hospital Meter, which is the only glucose meter cleared by the FDA for use with critically ill patients and CLIA-waived for use with ALL patients and ALL sample types. StatStrip Glucose has no known interferences and brings lab-like accuracy to bedside glucose testing - accuracy validated in an FDA submission study of 1,698 critically ill patients with 257 different and specific medical conditions, and over 8,000 medications, as well as over 200 published studies worldwide. StatStrip Glucose measures glucose and corrects for hematocrit, maltose, and other interferences that can cause erroneous results on other meters.

Related Links:
Nova Biomedical 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
All-in-One Molecular System
AIO M160
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.